Xeljanz is the first-in-class JAK inhibitor approved for psoriatic arthritis (PsA); it is also the only oral targeted therapy approved for this indication besides Celgene’s PDE-4 inhibitor Otezla. In recent years, multiple new therapies have been approved for the treatment of PsA. However, Xeljanz’s unique MOA, oral administration, and strong efficacy warrant the attention of both rheumatologists and dermatologists.
The PsA Emerging Therapies series includes three waves that will track the awareness, trial, and usage of Xeljanz since its approval in December 2017 for the treatment of PsA. In addition, the series will examine physician-anticipated future trends in PsA treatment,particularly Xeljanz uptake, as well as assess Pfizer’s promotional efforts.
- What is U.S. rheumatologists’ and dermatologists’ awareness of, familiarity with, and perception of Xeljanz?
- What patients are being prescribed Xeljanz, what are the reasons for prescribing, and how satisfied are physicians with Xeljanz?
- How do prescribers and nonprescribers compare across key metrics?
- How do the trial and adoption of Xeljanz compare with that of other recently launched products in the autoimmune market?
Emerging Therapies is a three-wave series based on primary research data collected at 1, 6, and 12 months post-commercial launch with U.S. physicians. The research captures physicians’ awareness, perceptions, and usage of the launched product as well as the impact on current therapies and anticipated future trends. We also provide insight on promotional efforts, prescriber and nonprescriber profiles, and benchmarking agents against other launched agents.
- Psoriatic Arthritis - Emerging Therapies - Xeljanz (tofacitinib) Psoriatic Arthritis - Wave 2 (US)
Author(s): Ritesh Gupta, PhD
Ritesh Gupta is a Lead Analyst on the immune and inflammatory disorders team at Decision Resources Group, whose work focuses primarily on Psoriatic Arthritis, Ulcerative Colitis and Crohn’s Disease.
He holds a Ph.D. degree in Cell Biology from Max Delbrück Center for Molecular Medicine, Berlin, where he worked on development of novel inhibitors for HGF/MET signaling pathways. Prior to joining DRG, Ritesh has worked as an assistant manager with BioXcel corporation and provided insights on various consulting projects. He was also associated with GVK Biosciences and worked on drug repurposing projects.